-
In late September, the fourth annual MedTec Ireland conference and trade show was held in the small but buzzing Irish city of Galway, sponsored by Canon Communications.
-
Sir George Alberti, head of emergency care for the UKs National Health Service (NHS), said that improvements in this area over the past two years have transformed its emergency care performance so that it is now the envy of the world. Speaking at a late-October breakfast reception at the home of Prime Minister Tony Blair, Alberti said that at the beginning of 2003, almost one-quarter of patients spent more than four hours in Accident and Emergency (A&E) units.
-
Thus far, the two drug-eluting stent (DES) products commercialized in the U.S. utilize a polymer as a method of incorporating drug and device. But the first-generation use of polymers may not be a model for future DES technologies, according to Martin Leon, MD, chairman of the Cardiovascular Research Institute (New York), in a presentation on the future of DES technologies during this years annual meeting of the American Heart Association (Dallas) in New Orleans.
-
Angiotech Pharmaceuticals (Vancouver, British Columbia) reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has expired pertaining to the proposed grant of an exclusive license to Boston Scientific (Natick, Massachusetts) with respect to the use of paclitaxel and other agents on medical devices in the coronary vascular field of use.
-
The annual scientific sessions of the American Heart Association (AHA; Dallas) primarily feature broad platforms for new product rollouts, an avalanche of clinical trials and even, occasionally, some interesting debate.
-
CryoCath Technologies (Montreal), a company developing cryotherapy products to treat cardiovascular disease, reported that its Freezor MAX catheter has received a supplemental premarket approval (PMA) indication from the FDA, allowing it to launch its fifth product into the U.S.
-
-
-
-
Eric Topol, MD, chief academic officer of the Cleveland Clinic, said during the Clinic-sponsored Medical Innovation Summit here in mid-October that those involved with or interested in innovation need to get away from the idea that every drug and device needs to be a blockbuster product.
